<DOC>
	<DOCNO>NCT00511953</DOCNO>
	<brief_summary>Depomed 's Gabapentin Extended Release investigational , extended release formulation gabapentin study treatment hot flash postmenopausal woman .</brief_summary>
	<brief_title>Study Gabapentin Extended Release ( G-ER ) Treatment Vasomotor ( Hot Flashes/Hot Flushes ) Symptoms Postmenopausal Women</brief_title>
	<detailed_description>The primary objective clinical trial determine optimal dose Gabapentin ER reduce number severity hot flash postmenopausal woman . Patients randomly assign Gabapentin ER placebo , 1 4 chance get placebo . The total study investigational treatment duration screen baseline 13 week . The primary endpoint trial compare number severity hot flash investigational treatment compare baseline . Sleep quality also evaluate .</detailed_description>
	<mesh_term>Hot Flashes</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>1 . Generally healthy , postmenopausal woman seek treatment hot flash . 2 . Patients use hormone replacement therapy ( HRT ) must willing discontinue treatment . 3 . Patients must experience least 7 moderate severe hot flash per day . 4 . Patient must willing commit 3 ( optionally 4 ) overnight stay study site include frequent blood sampling . Other inclusion apply . 1 . Patients hypersensitivity gabapentin . 2 . Patients severe chronic diarrhea , chronic constipation , uncontrolled irritable bowel syndrome ( IBS ) unexplained weight loss . 3 . Patients treat estrogen pellet injectable progestin drug therapy within 6 month . Other exclusion apply .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Hot flash</keyword>
	<keyword>Hot flush</keyword>
	<keyword>Postmenopausal symptom</keyword>
</DOC>